Skip to content

Anika Therapeutics, Inc.

ANIK

CIK 0000898437

← back to feed
Revenue (TTM)
$111.82M
−5.9% YoY Q1 Apr 2026
Net Income (TTM)
−$16.23M
+80.7% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.15
+80.2% YoY Q1 Apr 2026
Gross Margin
56.9%
Q1 Apr 2026
Operating Margin
-15.4%
Q1 Apr 2026
Net Margin
-14.5%
Q1 Apr 2026
Free Cash Flow (TTM)
−$16.17M
Q1 Apr 2026
Cash
$41.02M
Q1 Apr 2026
Total Debt
$26.6M
Q1 Apr 2026
Shares Outstanding
13.31M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings